# Categorical and dimensional aspects of stimulant medication effects in adult patients with ADHD and healthy controls

**Authors:** Per Thunberg, Maria Reingardt, Julia Rode, Mussie Msghina

PMC · DOI: 10.3389/fphar.2024.1412178 · Frontiers in Pharmacology · 2024-07-10

## TL;DR

This study shows that stimulant medication effects are clearer when grouping people by behavior rather than by ADHD diagnosis.

## Contribution

It demonstrates that dimensional stratification reveals clearer medication effects than categorical diagnostic groupings.

## Key findings

- Stimulant medication had no significant effects in categorical ADHD and control groups.
- Medication increased frontoparietal activation and shifted behavior in the reactive dimensional group.
- Dimensional grouping provided clearer insights into medication effects than diagnostic categories.

## Abstract

Psychiatric disorders are categorized on the basis of presence and absence of diagnostic criteria using classification systems such as the international classification of diseases (ICD) and the diagnostic and statistical manual for mental disorders (DSM). The research domain criteria (RDoC) initiative provides an alternative dimensional framework for conceptualizing mental disorders. In the present paper, we studied neural and behavioral effects of central stimulant (CS) medication in adults with attention deficit hyperactivity disorder (ADHD) and healthy controls using categorical and dimensional stratifications. AX-Continuous Performance Task (AX-CPT) was utilized for the later purpose, and participants were classified as “reactive” or “proactive” based on their baseline proactive behavioral index (PBI). Out of the 65 individuals who participated (33 healthy controls and 32 patients with ADHD), 53 were included in the final analysis that consisted of 31 healthy controls and 22 ADHD patients. For the dimensional stratification, a median split of PBI scores divided participants into “reactive” and “proactive” groups irrespective of whether they had ADHD or not. Participants performed AX-CPT in conjunction with functional magnetic resonance imaging (fMRI) before and after CS medication. We found no significant within or between group CS effect when participants were categorically assigned as healthy controls and ADHD patients. For the dimensional stratification, however, CS selectively increased activation in frontoparietal cognitive areas and induced a shift towards proactive control mode in the reactive group, without significantly affecting the proactive group. In conclusion, the neural and behavioral effects of CS were more clear-cut when participants were stratified into dimensional groups rather than diagnostic categories.

## Linked entities

- **Diseases:** attention deficit hyperactivity disorder (MONDO:0007743), ADHD (MONDO:0007743)

## Full-text entities

- **Diseases:** ADHD (MESH:D001289), Psychiatric disorders (MESH:D001523)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11266130/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11266130/full.md

## References

47 references — full list in the complete paper: https://tomesphere.com/paper/PMC11266130/full.md

---
Source: https://tomesphere.com/paper/PMC11266130